MEDIAN TECHNOLOGIES Aktie [WKN DE: A1JCLB / ISIN: FR0011049824]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu MEDIAN TECHNOLOGIES

08.07.22		Median Technologies to Participate in the 2022 European Congress of Radiology (ECR), July 13 – 17, 2022, Vienna, Austria, with Two Presentations on iBiopsy® (Businesswire)
07.07.22		Median Technologies to host a live webcast and provide a company update on July 12, 2022 (Businesswire)
13.06.22		Bryan Garnier & Co Initiates the Coverage of Median Technologies with a "Buy” Recommendation (Businesswire)
02.06.22		Median Technologies to Present an Abstract at the 2022 ASCO Annual Meeting, June 3 – 7, 2022, McCormick Place, Chicago, IL, USA (Businesswire)
31.05.22		Median Technologies Launches Imaging Lab, Spearheading the Integration of iBiopsy® Artificial Intelligence Technologies Into iCRO Imaging Services for Oncology Trials (Businesswire)
23.05.22		Median Technologies Announces the Availability of the Preparatory Documents for the Shareholders’ Ordinary and Extraordinary General Meeting on June 14, 2022 (Businesswire)
05.05.22		Median Technologies Is Moving Forward With the FDA Interactions for Its iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device (Businesswire)
21.04.22		Median Technologies Reports Full-Year 2021 Results and Business Indicators for the First Quarter of 2022 (Businesswire)
25.03.22		Median Technologies Brings Forward Its 2021 Annual Results Publication to April 21, 2022 (Businesswire)
22.03.22		Median Technologies Announces Design Completion of its iBiopsy® Lung Cancer Screening End-to-end CADe/CADx Software as Medical Device (SaMD) with Outstanding Sensitivity & Specificity Performance (Businesswire)
03.03.22		Median Technologies Files FDA 513(g) Regulatory Submission for iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device (Businesswire)
01.03.22		Median Technologies to Participate in the Cowen’s 42nd Annual Health Care Conference (Businesswire)
09.07.21		Median Technologies: Financial Communication Schedule for the Second Half Of 2021 (Businesswire)
08.07.21		Median Technologies' Business Continues to Grow at a Steady Pace in the First Half of 2021 (Unaudited Figures) (Businesswire)
08.04.21		Median Technologies Is Releasing Full Year 2020 Financial Results (audited) as Well as Q1 2021 Business Activity Indicators, Showing a Very Strong Growth (Businesswire)
16.02.21		iBiopsy®: Median Technologies Continues Its Strong Positioning in Early-Stage Diagnosis with a New iBiopsy® Clinical Development Plan on Lung Cancer Screening (LCS) (Businesswire)
09.02.21		iBiopsy®: Median Technologies Inks a Major Research Collaboration Agreement With the University of California San Diego (UC San Diego) (Businesswire)
14.01.21		Median Technologies Records a 51 % Increase of Its 2020 Annual Revenue (Unaudited Figures) (Businesswire)
05.01.21		Median Technologies: Financial Communications Schedule for the First Half of 2021 (Businesswire)
20.10.20		Median Technologies Records Its Eighth Consecutive Quarter of Revenue Growth (Businesswire)
14.10.20		Median Technologies Announces its H1 2020 Results (Businesswire)
08.09.20		Median Technologies: Promising Results on the Use of the IBiopsy® Platform in the Context of Measuring the Anti-tumor Immune Response (Businesswire)
27.08.20		Median Technologies: Financial Communications Schedule for the Second Half Of 2020 (Businesswire)
10.07.20		Half Year Median Technologies Liquidity Contract Statement Contracted with Louis Capital Markets UK LLP (Businesswire)
08.07.20		Median Technologies: Strong Business Activity for the First Half of 2020 (Unaudited Figures) (Businesswire)
06.07.20		Median Technologies Is Awarded the Euronext European Rising Tech Label (Businesswire)
01.07.20		Median Technologies to Host a Live Webcast and Provide a Company Update on July 9th, 2020 (Businesswire)
25.06.20		Median Technologies Appoints Oern Stuge MD, MBA, to Its Board of Directors (Businesswire)
17.06.20		Median Technologies: iBiopsy®: Promising Results on a Preliminary Study to Evaluate the Risk of Tumor Recurrence in Patients With Primary Liver Cancer (Businesswire)
04.05.20		Median Technologies: Liquidity Contract Transfer to Louis Capital Markets (Businesswire)
20.04.20		Median Technologies Receives a Disbursement of €15 Million, Corresponding to the First Tranche of the Loan Granted by the European Investment Bank (Businesswire)
14.04.20		Median Technologies Reports Full Year 2019 Financial Results (Businesswire)
02.03.20		Assistance Publique – Hôpitaux de Paris (AP-HP) And Median Technologies Reach a Research Collaboration Agreement Involving The iBiopsy® Platform (Businesswire)
20.01.20		Median Technologies: Financial Communications Schedule for the First Half of 2020 (Businesswire)
13.01.20		Median Technologies Announces Preliminary 2019 Unaudited Financial Results (Businesswire)
18.12.19		Median Technologies Announces the Signing of a € 35 Million Finance Contract with the European Investment Bank (EIB) (Businesswire)
08.10.19		Median Technologies’ Q3 Performance Shows Steady Growth, Validates the Strategy Adopted in 2018 (unaudited Figures) (Businesswire)
03.10.19		Median Technologies Reports Its Financial Results for H1 2019 (Businesswire)
11.07.19		Median Technologies Announces Preliminary H1 2019 Unaudited Financial Results (Businesswire)
08.07.19		AG Mednet and Median Technologies Partnership Supports Global Clinical Trials Portfolio, Including Extensive Programs in China (Businesswire)
28.06.19		Median Technologies: Financial Communications Schedule for the Second Half of 2019 (Businesswire)
21.05.19		Median Technologies to Attend the 2019 ASCO Annual Meeting, May 31 - June 4, 2019, McCormick Place, Chicago, IL, USA (Businesswire)
11.04.19		Median Technologies Reports Full Year 2018 Financial Results (Businesswire)
26.02.19		Median Technologies to Participate in the Cowen and Company 39th Annual Health Care Conference in Boston (Businesswire)
20.02.19		Median Technologies to Attend the 2019 European Congress of Radiology (ECR) from February 27 to March 3, 2019 in Vienna, Austria (Businesswire)
07.02.19		Median Technologies Provides a Company Update and Announces Preliminary Full Year 2018 Unaudited Financial Results (Businesswire)
01.02.19		Median Technologies: Financial Communications Schedule for the First Half of 2019 (Businesswire)
13.12.18		Median Technologies Appoints Dr. Nozha Boujemaa as Chief Science and Innovation Officer (Businesswire)
11.10.18		Median Technologies Reports Its Financial Results for H1 2018 and Announces Its Strategic Shift in Focus to Its Imaging Phenomics Platform iBiopsy® (Businesswire)
12.07.18		Median Technologies Receives the Forbes 2018 Futur40 Award and Special Recognition Prize for the "Health-Life Sciences” Company Category (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Diese AI-Aktie ist Cathie Woods neuer Favorit

JPMorgan: Bitcoin-Miner setzen auf Unternehmensmodell von MicroStrategy

NEL sichert sich Steuergutschrift in Millionenhöhe - Aktie sackt ab

ATX-Papier voestalpine-Aktie: So viel Verlust hätte ein voestalpine-Investment von vor einem Jahr eingefahren

Aktien von PVA TePla und SMA Solar springen hoch, VERBIO-Aktie stürzt ab: Jefferies-Analyst passt zahlreiche Bewertungen an

D-Wave Quantum-Aktie, IonQ-Aktie und Rigetti-Aktie fallen: Aktienrutsch geht trotz Beruhigungssignalen weiter

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	15.01.2025 16:05
Kaufwert:	EUR
	Hinzufügen Speichern